Antibiotic Skin Testing is the Appropriate Diagnostic Approach
For a patient with suspected immediate-type IgE-mediated antibiotic allergy, standard antibiotic skin testing should be performed rather than an autologous plasma skin test. Autologous plasma skin testing is not a validated or recommended diagnostic tool for antibiotic allergy evaluation. 1
Why Standard Antibiotic Skin Testing is Recommended
Validated Diagnostic Approach
Skin testing with the culprit antibiotic and relevant determinants is the established standard of care for evaluating immediate-type hypersensitivity reactions to antibiotics. 1, 2
For penicillin allergy specifically, the British Society for Allergy and Clinical Immunology recommends testing against benzylpenicilloyl poly-L-lysine (PPL), minor determinant mixture (MDM), amoxicillin, the index penicillin if known, and penicillin G. 1
The addition of PPL increases sensitivity by 15% and MDM by 47% for immediate-type penicillin hypersensitivity reactions. 1
Evidence Supporting Skin Testing
In a large study of 636 patients with suspected beta-lactam allergy, skin tests with PPL were positive in 46.8% and MDM in 43.7% of confirmed allergic patients, with 65.6% showing positive reactions to either PPL or MDM alone. 3
Among 290 proven penicillin-allergic patients, 70% had positive skin tests to at least one determinant, with amoxicillin being the most frequently positive reagent. 4
Skin testing provides a negative predictive value that allows safe drug provocation testing when negative, though the positive predictive value is generally accepted to be <50%. 1
Why Autologous Plasma Skin Testing is Not Appropriate
Lack of Validation
Autologous plasma skin testing has no established role in the diagnostic evaluation of antibiotic allergy. This test is not mentioned in any major allergy guidelines for antibiotic evaluation. 1
The provided evidence contains no references to autologous plasma skin testing as a diagnostic modality for antibiotic allergy, indicating it is not part of standard practice. 1, 2
Appropriate Use of Autologous Testing
- Autologous serum skin testing (ASST) is primarily used for chronic spontaneous urticaria to detect autoimmune mechanisms, not for drug allergy diagnosis. This is a completely different clinical context. 2, 5
Recommended Diagnostic Algorithm
Step 1: Risk Stratification Based on History
Recent reactions (<5 years) or severe immediate-type reactions require formal allergy work-up before re-exposure, regardless of timing. 1
Non-severe immediate-type reactions occurring >5 years ago may proceed directly to controlled drug challenge in some cases, but skin testing provides additional safety data. 1
Step 2: Perform Standard Skin Testing
Conduct prick tests followed by intradermal tests using non-irritating concentrations of the culprit antibiotic and relevant determinants. 3, 6
For penicillins: test PPL, MDM, amoxicillin, and the specific culprit drug if different. 1
For cephalosporins: test the specific cephalosporin in question at validated non-irritating concentrations, though standardized testing is less well-established than for penicillins. 6
Step 3: Interpret Results and Proceed
Negative skin tests: Proceed to drug provocation test (DPT) or graded challenge with the culprit antibiotic in a controlled setting with appropriate monitoring. 1
Positive skin tests: Confirm allergy and recommend avoidance; consider alternative antibiotics based on cross-reactivity patterns. 1, 6
Important Caveats
Limitations of Skin Testing
Sensitivity decreases over time, with patients losing skin test reactivity years after the initial reaction, particularly for amoxicillin-selective responders. 1
Skin testing has low sensitivity and specificity for non-severe, non-immediate, and vague reactions, particularly childhood rashes. 1
The positive predictive value of skin testing is <50%, meaning many patients with positive tests may actually tolerate the drug, though ethical considerations prevent routine challenge in these cases. 1
When to Consider Direct Challenge Instead
Low-risk patients with remote, mild, non-IgE-mediated reactions may proceed directly to graded drug challenge without skin testing, as the utility of skin tests is very low in this population. 1
Direct DPT without skin testing is increasingly supported for non-severe reactions, particularly in children, with studies showing only 1.5-6% reaction rates and no life-threatening anaphylaxis. 1